Success Metrics

Clinical Success Rate

62.5%

Based on 5 completed trials

Completion Rate

63%(5/8)

Active Trials

0(0%)

Results Posted

20%(1 trials)

Terminated

3(38%)

Phase Distribution

Ph phase_2

13%

Ph not_applicable

13%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

6(75.0%)

Phase 2Efficacy & side effects

1(12.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(3)

Detailed Status

Completed5

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

62.5%

Most Advanced

Phase 2

Trials by Phase

Phase 16 (75.0%)

Phase 21 (12.5%)

N/A1 (12.5%)

Trials by Status

terminated338%

completed563%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_1

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

NCT00217373

terminatedphase_1

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

NCT00088933

completednot_applicable

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

NCT00091039

completedphase_2

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

NCT00052351

terminatedphase_1

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

NCT00009958

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT00217373Phase 1

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

Completed

NCT00088933Phase 1

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Terminated

NCT00091039Not Applicable

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

Completed

NCT00052351Phase 2

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Completed

NCT00009958Phase 1

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

Terminated

NCT00028496Phase 1

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Completed

NCT00128622Phase 1

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer